Skip to main content
. 2012 Oct 29;7(10):e48239. doi: 10.1371/journal.pone.0048239

Figure 1. Schematic depiction of the MOPC315 model.

Figure 1

(A) The MHCII negative MOPC315 cells secrete the IgA myeloma protein M315. This protein is endocytosed and processed by antigen-presenting cells (APCs), and CD4+ T cells with transgenic TCRs recognize a myeloma-derived idiotypic (Id315) peptide in the context of the MHC class II I-Ed molecule. (B) Normal BALB/c mice are susceptible to tumor development upon injection with MOPC315 cells, while mice with the Id315-TCR transgene are resistant towards tumor development. Resistance is mediated by tumor specific (Id-specific) TCR transgenic CD4+ T cells [16]–[19].